A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms BASE
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 08 Sep 2017 Planned number of patients changed from 5000 to 4000.
    • 08 Sep 2017 Planned End Date changed from 1 Jan 2023 to 20 Jul 2022.
    • 08 Sep 2017 Planned primary completion date changed from 1 Jan 2019 to 26 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top